MicroRNAs as a Diagnostic Marker and a Therapeutic Target for Alzheimer’s Disease

Abstract

Alzheimer’s disease (AD) is a progressive, neurodegenerative disease and is the most common cause of dementia. The disease pathology of AD is marked by the accumulation of Beta amyloid (Aβ) plaques and deposition of phosphorylated tau NFTs in the brain. Currently, the therapeutic approaches to AD are solely palliative in nature and thus can do little to stop or reverse the disease pathology once it has begun. MicroRNAs (miRNAs) are a class of noncoding nucleotides that are critically involved in the regulation of various posttranscription mRNA processes, such as synapse plasticity and neuron differentiation. Owing to the multifactorial nature of AD, miRNAs have garnered much attention in the research field due to their concomitant dysregulation and appearance in several AD pathophysiological processes. This review paper offers insight into the potential use of miRNAs as a therapeutic target and diagnostic marker in AD.